Psoriasis Research Today is a free monthly online journal that collates and summarizes the latest research about Psoriasis, including details on treatment, prevention, medication, causes.

Volume 4 (2007), Issue 12 (December)

1. Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis.
   J Invest Dermatol, 128(1): 67-78. [Abstract] [Full-text]
2. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor.
   J Invest Dermatol, 128(1): 110-24. [Abstract] [Full-text]
3. Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse.
   J Invest Dermatol, 128(1): 125-30. [Abstract] [Full-text]
4. MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices.
   Rheumatology (Oxford), 47(1): 92-5. [Abstract] [Full-text]
5. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study.
   Ann Rheum Dis, 67(1): 26-30. [Abstract] [Full-text]
6. Infliximab in dermatological treatment: beyond psoriasis.
   Expert Opin Biol Ther, 8(1): 123-33. [Abstract] [Full-text]
7. Incidence and risk factors for psoriasis in the general population.
   Arch Dermatol, 143(12): 1559-65. [Abstract] [Full-text]
8. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens.
   Arch Dermatol, 143(12): 1515-9. [Abstract] [Full-text]
9. The risk of mortality in patients with psoriasis: results from a population-based study.
   Arch Dermatol, 143(12): 1493-9. [Abstract] [Full-text]
10. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
    J Am Acad Dermatol, 58(1): 116-24. [Abstract] [Full-text]
11. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
    J Am Acad Dermatol, 58(1): 125-35. [Abstract] [Full-text]
12. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
    J Am Acad Dermatol, 58(1): 94-105. [Abstract] [Full-text]
13. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    J Am Acad Dermatol, 58(1): 106-15. [Abstract] [Full-text]
14. Psoriasis is associated with increased beta-defensin genomic copy number.
    Nat Genet, 40(1): 23-5. [Abstract] [Full-text]

© 2004-2008 Psoriasis Research Today. All Rights Reserved.